Project Grant R01HL185164
Award Date 7/15/26
Completion Date 3/31/28
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded University of California, Los Angeles $1,574,590 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 15, 2026, with a completion date of March 31, 2028. This Project Grant funds basic and translational research to elucidate the role of alternative polyadenylation (APA) in cardiovascular disease and lipid metabolism. The research integrates computational, molecular, cellular, and...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $811,885 to the J. David Gladstone Institutes under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025. The award funds research to elucidate epigenomic mechanisms of cardiac fibrosis and heart failure pathogenesis, with a completion date of May 31, 2029. The research leverages novel genetic mouse models, advanced transcriptional and epigenomic...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $1,072,936 to the University of California, San Diego, effective September 15, 2025, through June 30, 2029, under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports fundamental research investigating protein aggregation mechanisms in hematopoietic stem cells (HSCs), with the primary deliverable being scientific research and discovery designed to advance...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $231,552 Project Grant to the University of California, San Diego on September 16, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). This research project, titled "Tissue Elasticity and Viscosity Modulates Macrophage-Fibroblast Signaling in Cardiac Fibrosis," focuses on investigating the mechanisms underlying cardiac fibrosis through the study of interactions between...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $711,796 Project Grant to the University of California, Irvine, effective July 1, 2026, through April 30, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). The project will develop a nanomaterial-engineered proteomic (NANOPRO) platform designed to map curvature-dependent cardiac signaling by creating unbiased, 20-nanometer-resolution proteomic atlases of distinct membrane...
- Federal Grant Award Summary Brigham and Women's Hospital Inc. received a $1.24 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective March 1, 2026, through February 28, 2033. The award supports investigative research into non-coding RNAs (ncRNAs)—including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs)—and their roles in chronic limb-threatening ischemia (CLTI) associated with peripheral...
- Federal Project Grant Award Summary New York University's Long Island School of Medicine received a $2.73 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 24, 2025, with completion targeted for August 31, 2027. The award funds research to develop and validate C2, a novel synthetic microRNA-30c analog, as a therapeutic intervention to reduce plasma cholesterol levels and mitigate...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $150,104 to the Regents of the University of Colorado (University of Colorado-Denver) on January 26, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The project, titled "Lysine Myristoylation as a Novel Mechanism for Regulating PKA in the Heart," will be completed by December 31, 2028. The research investigates an alternative mechanism to activate protein kinase A (PKA)...
- Federal Project Grant Award Summary New York University School of Medicine received a $1.69 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 1, 2026, and scheduled for completion by April 30, 2028. The grant funds research to elucidate the molecular mechanisms and therapeutic potential of CHROMR, a long noncoding RNA (lncRNA) implicated in atherosclerotic cardiovascular disease (ASCVD)....
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham a Project Grant of $535,556 under the Cardiovascular Diseases Research program (CFDA 93.837) effective August 1, 2025, with completion targeted for May 31, 2030. This award supports research to elucidate the role of a novel mechanosensitive histone modification (H3T32 O-GlcNAc) in atherosclerosis pathogenesis. The research investigates how atheroprone shear stress...